DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
▼ + stars: | 2024-06-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The company said it plans to invest $6.8 billion in production this year, up from roughly $4 billion last year. Construction of the 1.4 million-square-foot facility has begun and is expected to be completed between 2027 and 2029, Novo Nordisk said. Twelve other production sites are located in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, according to a Novo Nordisk spokesperson. Around 35,000 U.S. patients on average start Wegovy each week today, up from roughly 27,000 in May, a Novo Nordisk spokesperson said in a statement.

Persons: Doug Langa, Clayton —, Langa, Eli Lilly Organizations: Novo Nordisk, Danish, Novo Nordisk's, Drug Administration Locations: Clayton , North Carolina, U.S, Novo, North Carolina, Clayton, Durham , North Carolina, West Lebanon , New Hampshire, Denmark, France, China, Japan, Algeria, Brazil, Iran, Russia

☆ SIRO, One Za’abeel: Dubai’s ‘first fitness hotel’ is taking wellness tech to the next level
▼ + stars: | 2024-06-21 | by ( Rebecca Cairns | ) edition.cnn.com time to read: +8 min

“The industry is evolving,” says Desmond Cawley, hotel manager at SIRO, One Za’abeel. This kind of light therapy treatment has its roots in NASA’s experimentation with red light therapy in the 1990s to boost plant growth in space and help heal wounds in astronauts. Rebecca Cairns/CNNEven at SIRO, with all its cutting-edge tech, Cawley has observed a surge of interest in mindfulness activities like meditation. Of course, at SIRO, there’s even a high-tech alternative to this: “vibroacoustic therapy,” the sci-fi equivalent of a gong bath. Tech to help you disconnect might seem excessive, but for SIRO, the integration of health data is the future of wellness, providing guests with a data-driven, personalized wellness program.

Persons: ”, Desmond Cawley, SIRO, Dubai’s, Adam Peaty, Ramla Ali, Cawley, it’s, Rebecca Cairns, Boka, “, Beth McGroarty, that’s, ” McGroarty, SIRO isn’t, McGroarty, —, there’s Organizations: CNN, AC Milan football, Kerzner, Global Wellness Institute, bros, Equinox Locations: Dubai, Montenegro, New York City, SIRO, Cryotherapy

☆ Weight loss drug contender Zealand Pharma jumps 23% on trial results
▼ + stars: | 2024-06-21 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. LONDON — Shares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. Petrelintide was "judged to be safe and well tolerated at all dose levels" and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release. GLP-1RA-based treatments include Ozempic, the diabetes drug produced by fellow Danish pharmaceutical firm Novo Nordisk , which has exploded in popularity globally for its weight-loss effects. Soaring demand for Ozempic and obesity drug Wegovy have propelled Novo Nordisk to become Europe's most valuable company.

Persons: Petrelintide Organizations: Novo Nordisk, Denmark's Zealand Pharma, Zealand Pharma Locations: Hillerod, Denmark, Danish

☆ This little-known biotech stock is primed to surge nearly 50%, Canaccord says
▼ + stars: | 2024-06-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Positive data from Intra-Cellular Therapies ' latest study could herald further success for the biotechnology stock, according to Canaccord Genuity. The updated forecast implies that shares of Intra-Cellular Therapies could soar nearly 50% from their Tuesday close at $75.48. "We believe the solidity of the Phase 3 data means an approval for luma in MDD is more of a when, not if." Shares of Intra-Cellular Therapies have risen less than 4% this year. But the analyst believes the stock has been "somewhat constrained" due to investors' overly cautious nature with luma's potential patent runway, he wrote.

Persons: Canaccord, Sumant Kulkarni, Kulkarni, —, Fred Imbert Organizations: Therapies, Cellular Locations: MDD

☆ 6 types of depression identified in Stanford study
▼ + stars: | 2024-06-20 | by ( Kristen Rogers | ) edition.cnn.com time to read: +11 min

Some 30% to 40% of people with depression do not experience symptom improvement after trying one treatment, according to the study. And about 30% of people diagnosed with depression go on to experience treatment-resistant depression when the disorder doesn’t improve after multiple treatment attempts. Mapping depression in the brainThe authors used data from 801 adult participants who were previously diagnosed with depression or anxiety, and 137 healthy control group participants. The grant supports a five-year project involving 4,500 participants, which is centered on the development of a better diagnosis and treatment tool for depression biotypes. This method isn’t intended to replace or be the primary choice for assessments of individual cases of depression, Williams said.

Persons: biotypes, ”, Leanne Williams, Vincent V.C, Woo, Williams, Anhedonia, Jun Ma, Ma, Beth, George Vitoux, “, Richard Keefe, wasn’t, Keefe, Jonathan Alpert, Dorothy, Marty Silverman, Alpert, ” Keefe, you’re Organizations: Lifeline, CNN, Nature Medicine, Psychiatry, Behavioral Sciences, Stanford University School of Medicine, Stanford Center, Precision Mental Health, Wellness, Medicine, University of Illinois, Duke University Medical Center, Montefiore Medical, Albert Einstein College of Medicine, Psychiatric Association’s Council, Research, National Institute of Mental Health, National Institutes, Health’s, Mental Health Initiative Locations: California, United States, University of Illinois Chicago, North Carolina, New York City, Stanford

☆ Having an only child means we have more time and resources for her. But it doesn't make her spoiled.
▼ + stars: | 2024-06-17 | by ( Sara Rowe Mount | ) www.businessinsider.com time to read: +4 min

As the parent of an only child, I often field questions like, "Does she have any siblings?" I considered having more kids before I got pregnantAt one point, I considered having more than one child. Unsurprisingly, my husband was fully on board with never, ever having to go through it all again. Being a mother is still incredibly challenging for meAs an only child my daughter does get more by default. AdvertisementMy daughter's developmental delays and autism mean she needs more of my physical and emotional reserves than a neurotypical child.

Persons: brats, I've, I'm Organizations: Service Locations: Colorado

☆ Brain science start-up Neuroelectrics uses electricity and a headcap to reduce seizures in patients with epilepsy. Now it needs FDA approval
▼ + stars: | 2024-06-14 | by ( Cristy Garratt Maria Gomez De Sicart | Cristy Garratt | Https | ) www.cnbc.com time to read: +1 min

High up in the hills of Barcelona, brain science start-up Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. Its main product is a headcap, which monitors the brain's electrical activity and stimulates regions of the brain with mild electrical currents. Co-founder and CEO Ana Maiques believes it will significantly improve the lives of people suffering with epilepsy. In addition to epilepsy, Maiques and her team are optimistic that the headgear can also be used to treat depression and Alzheimer's. So, when you have epilepsy, you have an electrical discharge in one area of your brain, so they can really target and help them," said Roser Sanchez-Todo, R&D director for Neuroelectrics' brain modelling department.

Persons: Ana Maiques, Maiques, Roser Sanchez, Neuroelectrics Organizations: CNBC Tech, U.S . Food, Drug Administration Locations: Barcelona

☆ Internet addiction may harm the teen brain, MRI study finds
▼ + stars: | 2024-06-04 | by ( Kristen Rogers | ) edition.cnn.com time to read: +8 min

A new study has possibly captured that objectively, finding that for teens diagnosed with internet addiction, signaling between brain regions important for controlling attention, working memory and more was disrupted. Specifically, internet ‘addiction,’ which was initially conjured up by (psychiatrist) Ivan K. Goldberg in 1995 as a joke. Das wasn’t involved in the study. “Overall, the mechanisms underlying internet addiction are more like an emerging pattern than a finished picture,” Chang said. “Similar to substance and gambling disorders, internet addiction rewires the brain, making it harder to resist internet related stimuli,” he added.

Persons: ”, Max Chang, ” Dr, David Ellis, Ellis, wasn’t, Ivan K, Goldberg, ’, ” Ellis, isn’t, Eva Telzer, ” Telzer, Smita Das, Das wasn’t, Caglar, Yildirim wasn’t, ” Chang, Chang, Yildirim, Das, ” Das, “ Organizations: CNN — Teens, Mental Health, Brigade, Family Service, University of Bath’s Institute for Digital Security, Disorders, University of North, Chapel Hill, Stanford Medicine, Khoury College of Computer Sciences, Northeastern University, American Psychiatric Association, APA Locations: San Francisco, United States, Asia, China, University of North Carolina, Chapel, California, Boston, APA’s

☆ Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
▼ + stars: | 2024-06-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drugmaker believes it can almost double revenue by 2030. The pharmaceutical giant also plans to release 20 new drugs by 2030, half of which will treat cancer, Soriot said. The company recently released promising results about several of its cancer drugs at the American Society of Clinical Oncology's annual meeting, including ones for lung and breast cancers. Soriot said researchers are quickly developing new and promising cancer treatments. He said new cell therapies have the potential to cure patients, and he also pointed to antibody-drug conjugates — which, unlike chemotherapy, aim to target cancer cells while sparing healthy ones.

Persons: Pascal Soriot, CNBC's Jim Cramer, we're, Soriot Organizations: AstraZeneca, American Society, Clinical, CNBC

I've spent a lot on vet visits for my dog, so I decided to look into what pet insurance I could get. In the last year, she's had a series of vet visits that left us with a few thousand dollars in bills to pay. I decided to price out three popular pet insurance plans to figure out which one is right for us. It offers a bundling discount of up to 10%, making my pet insurance premiums cheaper than any other provider. Plus, I received an insurance bundling discount because I already had other insurance plans through the company.

Persons: I've, she's, it's, —, Figo

☆ How to make money from medical research and donations
▼ + stars: | 2024-05-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +7 min

Sell your blood plasmaBags of blood plasma being examined in a laboratory. During plasma donation, blood is drawn and an automated machine separates the plasma from other blood components, which are returned to the donor. Plasma donation pay varies from site to site, but the average payout is typically around $50 per donation. During the egg donation cycle, patients are injected with fertility drugs so that the ovaries make more mature eggs than normal. For example, here's a list of the most recent paid research studies offered by New York University.

Persons: —, Weill, You'll, what's, Carolina Reid, Stacy Thacker Organizations: Service, Business, Weill Cornell, of California, NASA, US Air Force Reserve, Institutes of Health, US Food and Drug Administration, New York University, NYU, Associated Press, Science Locations: United States, Houston , Texas

☆ My son was diagnosed with autism at age 5. I spent decades hoping he'd change — but now I accept him as he is.
▼ + stars: | 2024-05-28 | by ( Maribeth Smillar | ) www.businessinsider.com time to read: +4 min

He was diagnosed with autism at the age of 5. But I haven't spent my life hoping that Evan will be accepted. I've spent my life hoping that he will change. At times, I know I have failed them, but Evan is the one I have let down the most. In that pure and still place, I started to let go of what I had hoped would be and began to accept what was.

Persons: Evan, I've, Jamie, unfazed, Evan wouldn't, Evan doesn't, Long, Gray sweatpants Organizations: Service, Business, Celtics

☆ Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds
▼ + stars: | 2024-05-24 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Diabetes is a key risk factor for kidney disease, which is one of the leading causes of death in the United States and worldwide; about 1 in 3 people with diabetes also has chronic kidney disease, according to the US Centers for Disease Control and Prevention. But new research shows that weekly injections of semaglutide cut the risk of severe outcomes from diabetic kidney disease by about 24%. The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. “Kidney disease attributed to diabetes, or diabetic kidney disease, is one of the most common and deadly complications of diabetes. Yet, unfortunately, there’s very low awareness around it,” said Dr. Katherine Tuttle, chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology.

Persons: ”, Vlado Perkovic, “ Semaglutide, Martin Holst Lange, Katherine Tuttle, ” It’s, Tuttle, semaglutide, It’s, Dr, Sanjay Gupta, White, ” Tuttle Organizations: CNN, Diabetes, US Centers for Disease Control, New England, of Medicine, European Renal Association Congress, University of New, University of New South Wales Sydney, Novo Nordisk, American Society of Nephrology, Providence Inland Northwest Health, Health Sciences, University of Washington, CNN Health Locations: United States, University of New South, Danish, American

☆ The reverse lunge: Strengthen and soothe aching knees with this lunge variation
▼ + stars: | 2024-05-24 | by ( Katia Hetter | Dana Santas | ) edition.cnn.com time to read: +7 min

In the case of knee pain, there’s one simple yet effective exercise I favor to help alleviate pain and strengthen the muscles around your knees: the reverse lunge. Common causes of knee pain include:• Osteoarthritis: a degenerative joint disease that results in the breakdown of cartilage. Addressing knee pain often requires a multifaceted approach that may include physical therapy, lifestyle modifications, medication and targeted exercises such as the reverse lunge. How to perform a reverse lungeThe reverse lunge can also improve your core strength. Aaron LockwoodPerforming a reverse lunge correctly is crucial to reaping its benefits and avoiding injury.

Persons: Dana Santas, •, “, ”, Aaron Lockwood Organizations: Pain, CNN, CNN’s

☆ A corner of the cancer therapy market is heating up—Here are the names investors need to know
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +8 min

A $25 billion market Meanwhile, RBC Capital Markets sees a $25 billion market opportunity for the space. A name Jones likes is Perspective Therapeutics , which he rates outperform. CATX 1Y mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. So it's really an ideal profile," said Piper Sandler analyst Edward Tenthoff, who doesn't cover Perspective Therapeutics. Then there is Lantheus Holdings , which calls itself a radiopharmaceutical-focused company and has a $5.6 billion market cap.

Persons: There's, Eli Lilly, Myers, Jefferies, Andrew Tsai, radiopharma, Oppenheimer, Jeff Jones, FactSet, William Blair, Read, — it's, Andy Hsieh, Gregory Renza, Jones, Cantor Fitzgerald, Louise Chen, it's, Piper Sandler, Edward Tenthoff, Dan Lyons, Janus Henderson, Lantheus, Roanna Ruiz Organizations: Novartis, pharma, Mariana Oncology, Myers Squibb, AstraZeneca, Fusion Pharmaceuticals, RBC Capital Markets, TRT, Therapeutics, Alpha, Janus, Janus Henderson Investors, Lantheus Holdings, Lantheus, Leerink, ~$ Locations: Biopharma, Bristol, Mariana, radiopharma, New Jersey

☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +7 min

RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance

Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol

☆ If you're not making progress in therapy, you might be intellectualizing your emotions. Here are 3 signs, according to a therapist.
▼ + stars: | 2024-05-21 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +7 min

You might fixate on understanding why you're feeling this way, why the upsetting situation has occurred, and what you can rationally do to resolve it. AdvertisementShe shared three signs that you might be intellectualizing your feelings and how you can start to feel safe enough to feel them. The goal of therapy should be to support when you're feeling safe enough that you want to feel your feelings." You feel emotionally disconnected from people and things in your lifeFeeling a sense of emptiness or disconnection could be a sign you're intellectualizing your feelings. You're responding normally but you don't feel fully authentic or present because you're thinking too much and you're "stuck in your head."

Persons: —, Trisha Wolfe, Wolfe, they've, They'll, I'm, Intellectualizing Organizations: Service, Business, Systems Locations: Michigan, intellectualizing

☆ ElevateBio CEO on disruptive potential for gene and cell therapies
▼ + stars: | 2024-05-14 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailElevateBio CEO on disruptive potential for gene and cell therapiesDavid Hallal, ElevateBio CEO, joins 'Fast Money' to talk making CNBC's Disruptor 50 list, what is included in its portfolio, innovation in cell and gene therapy and more.

Persons: David Hallal

☆ Atlantis The Royal, Dubai: Inside the Middle East’s ‘best’ hotel
▼ + stars: | 2024-05-07 | by ( Rebecca Cairns | ) edition.cnn.com time to read: +9 min

Atlantis, The Royal Atlantis, The Royal: The double-height bar is perfect for sunset cocktails — although you won't be making your own drinks, as there's a 24-hour bartender ready to make your favorites. Atlantis, The Royal Atlantis, The Royal: The triple-height library provides a secluded space to work, read or relax. Atlantis, The Royal Atlantis, The Royal: The entertainment room is kitted out with a 98-inch LED screen for a home cinema experience. Atlantis, The Royal Atlantis, The Royal: Every room has stunning views — including the marble-clad bathrooms. Atlantis, The Royal Atlantis, The Royal: Guests can enjoy designer amenities made by French fashion house Hermès, as well as bespoke gold toothbrushes, combs and brushes.

Persons: Swedish House Mafia —, there’s, ”, Tom Roelens, There’s, Cabana, Rebecca Cairns, Kendall Jenner, “ We’ve, we’ve, Graff, bathrobes, Jay Z, Louis, Valentino —, “, it’s, Estiatorio Milos, Costas Spiliadis, — Organizations: CNN, Swedish House Mafia, Royal, Atlantis Resorts, Dolce, Gabbana, cabanas, Atlantis, “ Royal, Nobu, —, Chefs, Sky Locations: Dubai, Beyoncé, isn’t, Arabian, Atlantis Royal Dubai

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ Experimental gene therapy restores some vision in patients with inherited blindness
▼ + stars: | 2024-05-06 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +16 min

“Now, post-surgery and post recovery, I am able to see in dimmer lighting with my left eye,” Cook said. A treatment that used CRISPR was found to be safe and efficacious in improving vision among a small sample of patients with inherited blindness in the Phase 1/2 clinical trial that Cook participated in. Months following the treatment, Cook was sitting with friends on a balcony that had Christmas lights wrapped around the railing. Courtesy Olivia CookBefore the treatment, Cook said that she sometimes could conceal the vision challenges she has had. Mass Eye and EarKalberer described the CRISPR treatment as “groundbreaking,” but warned it’s not a cure.

Persons: Olivia Cook, Cook, ”, ” Cook, “, I’ve, “ I’d, you’d, CRISPR, Eric Pierce, Brigham, “ We’re, ” Pierce, Jason Comander, ‘, Michael Kalberer, Kalberer, it’s, “ It’s, It’s, Pierce, Editas, We’re, Art Caplan, ” Caplan, —, Vlad Diaconita, ” Diaconita, Dr, Sanjay Gupta, Aliaa Abdelhakim Organizations: CNN, Missouri State University, New England, of Medicine, Mass, Harvard Medical School, Editas Medicine, Perelman School of Medicine, University of Pennsylvania, University of Michigan, University of Miami, Oregon Health & Science University, US Food and Drug Administration, CEP290, pharma, NYU Grossman School, Medicine’s Department of Population Health, Columbia University Vagelos College of Physicians and Surgeons, CNN Health Locations: Springfield, United States, CEP290

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ Anger can harm your blood vessel function, study shows
▼ + stars: | 2024-05-01 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +4 min

Feelings of anger adversely affect blood vessel health, according to a study published Wednesday in the Journal of the American Heart Association. How 40 minutes could turn into a longer problemResearchers in this study observed three major ways that anger impacted blood vessel health, Shimbo said. First, it made it harder for blood vessels to dilate in response to ischemia, or a restriction, he said. After the eight-minute task meant to induce anger, the impacts on blood vessels were seen for up to 40 minutes, he said. Maybe there are ways — such as exercise or medication — to treat the adverse effects of anger on blood vessels, he speculated.

Persons: ”, Daichi Shimbo, Shimbo, Joe Ebinger, ” Ebinger, Anger, Ebinger, Brett Ford, Deborah Ashway, Ashway Organizations: CNN, American Heart Association, Columbia University, Smidt Heart, University of Toronto Scarborough Locations: New York City, Cedars, Sinai, Los Angeles, New Bern , North Carolina

☆ GE Healthcare's disappointing first quarter offers both a lesson and an opportunity
▼ + stars: | 2024-04-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +10 min

GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell slightly short of the Wall Street consensus. GE Healthcare Why we own it : GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. That's what we have to say about this GE Healthcare quarter. This contributed to some of the softness in the first quarter quarter. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: didn't, GE Healthcare's, —, it's, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, LSEG, General Electric, Philips, Siemens, GE Healthcare YTD, GE, Management, Alzheimer's, CNBC, Getty Locations: China, Covid, Jena , Germany

Search resuls for: "Therapies"

25 mentions found